Last reviewed · How we verify
Direct-acting antiviral agents
Direct-acting antiviral agents is a Direct-acting antiviral Small molecule drug developed by Qing XIe. It is currently in Phase 2 development for Hepatitis C, Hepatitis B. Also known as: daclatasvir, asunaprevir, ombitasvir, paritaprevir.
Direct-acting antiviral agents target viral replication by inhibiting viral enzymes or proteins.
Direct-acting antiviral agents target viral replication by inhibiting viral enzymes or proteins. Used for Hepatitis C, Hepatitis B.
At a glance
| Generic name | Direct-acting antiviral agents |
|---|---|
| Also known as | daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir |
| Sponsor | Qing XIe |
| Drug class | Direct-acting antiviral |
| Target | Viral enzymes or proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Direct-acting antiviral agents work by directly inhibiting viral enzymes or proteins, thereby blocking viral replication. This class of drugs includes protease inhibitors, polymerase inhibitors, and integrase inhibitors, among others.
Approved indications
- Hepatitis C
- Hepatitis B
Common side effects
- Fatigue
- Nausea
- Headache
Key clinical trials
- People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents (PHASE4)
- First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics (PHASE1)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (PHASE2)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients (PHASE2)
- Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder (PHASE2, PHASE3)
- Drug-Drug Intercations and Direct Acting Antiviral Agents Against HCV
- HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Direct-acting antiviral agents CI brief — competitive landscape report
- Direct-acting antiviral agents updates RSS · CI watch RSS
- Qing XIe portfolio CI
Frequently asked questions about Direct-acting antiviral agents
What is Direct-acting antiviral agents?
How does Direct-acting antiviral agents work?
What is Direct-acting antiviral agents used for?
Who makes Direct-acting antiviral agents?
Is Direct-acting antiviral agents also known as anything else?
What drug class is Direct-acting antiviral agents in?
What development phase is Direct-acting antiviral agents in?
What are the side effects of Direct-acting antiviral agents?
What does Direct-acting antiviral agents target?
Related
- Drug class: All Direct-acting antiviral drugs
- Target: All drugs targeting Viral enzymes or proteins
- Manufacturer: Qing XIe — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Hepatitis C
- Indication: Drugs for Hepatitis B
- Also known as: daclatasvir, asunaprevir, ombitasvir, paritaprevir, dasabuvir
- Compare: Direct-acting antiviral agents vs similar drugs
- Pricing: Direct-acting antiviral agents cost, discount & access